The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products
- 1 January 1997
- journal article
- review article
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 11 (1) , 6-14
- https://doi.org/10.1016/s0887-7963(97)80005-3
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Summary of clinical experience with recombinant factor VIII products — KogenateAnnals of Hematology, 1994
- Hemophilia ANew England Journal of Medicine, 1994
- Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices CommitteeTransfusion, 1993
- Life expectancy of Swedish haemophiliacs, 1831–1980British Journal of Haematology, 1985
- Molecular cloning of a cDNA encoding human antihaemophilic factorNature, 1984
- Structure of human factor VIIINature, 1984
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984
- Characterization of the human factor VIII geneNature, 1984
- Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitateTransfusion, 1984
- Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag SystemNew England Journal of Medicine, 1965